Molecular Alterations in Malignant Pleural Mesothelioma : A Hope for Effective Treatment by Targeting YAP
© 2022. The Author(s)..
Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide. While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. The morphological analysis of the histological subtyping remains the primary indicator for therapeutic decision making at an advanced disease stage, while a platinum-based chemotherapy regimen combined with pemetrexed, either with or without bevacizumab, is still the main treatment option. Consequently, malignant pleural mesothelioma still represents a significant health concern owing to poor median survival (12-18 months). Given this context, both diagnosis and therapy improvements require better knowledge of the molecular mechanisms underlying malignant pleural mesothelioma's carcinogenesis and progression. Hence, the Hippo pathway in malignant pleural mesothelioma initiation and progression has recently received increasing attention, as the aberrant expression of its core components may be closely related to patient prognosis. The purpose of this review was to provide a critical analysis of our current knowledge on these topics, the main focus being on the available evidence concerning the role of each Hippo pathway's member as a promising biomarker, enabling detection of the disease at earlier stages and thus improving prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Targeted oncology - 17(2022), 4 vom: 29. Juli, Seite 407-431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dubois, Fatéméh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04Q9AIZ7NO |
|---|
| Anmerkungen: |
Date Completed 04.08.2022 Date Revised 30.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11523-022-00900-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344262154 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344262154 | ||
| 003 | DE-627 | ||
| 005 | 20231226022345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-022-00900-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344262154 | ||
| 035 | |a (NLM)35906513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dubois, Fatéméh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular Alterations in Malignant Pleural Mesothelioma |b A Hope for Effective Treatment by Targeting YAP |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2022 | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide. While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. The morphological analysis of the histological subtyping remains the primary indicator for therapeutic decision making at an advanced disease stage, while a platinum-based chemotherapy regimen combined with pemetrexed, either with or without bevacizumab, is still the main treatment option. Consequently, malignant pleural mesothelioma still represents a significant health concern owing to poor median survival (12-18 months). Given this context, both diagnosis and therapy improvements require better knowledge of the molecular mechanisms underlying malignant pleural mesothelioma's carcinogenesis and progression. Hence, the Hippo pathway in malignant pleural mesothelioma initiation and progression has recently received increasing attention, as the aberrant expression of its core components may be closely related to patient prognosis. The purpose of this review was to provide a critical analysis of our current knowledge on these topics, the main focus being on the available evidence concerning the role of each Hippo pathway's member as a promising biomarker, enabling detection of the disease at earlier stages and thus improving prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Pemetrexed |2 NLM | |
| 650 | 7 | |a 04Q9AIZ7NO |2 NLM | |
| 650 | 7 | |a Asbestos |2 NLM | |
| 650 | 7 | |a 1332-21-4 |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 700 | 1 | |a Bazille, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Levallet, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Maille, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Brosseau, Solenn |e verfasserin |4 aut | |
| 700 | 1 | |a Madelaine, Jeannick |e verfasserin |4 aut | |
| 700 | 1 | |a Bergot, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Zalcman, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Levallet, Guénaëlle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d 2009 |g 17(2022), 4 vom: 29. Juli, Seite 407-431 |w (DE-627)NLM187616825 |x 1776-260X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:4 |g day:29 |g month:07 |g pages:407-431 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11523-022-00900-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 4 |b 29 |c 07 |h 407-431 | ||